Intrathecal treatment using autologous mesenchymal stem cell neural progenitors (MSC-NP) may improve established disability in MS: results of a phase I open-label trial

Staff: 
Saud A. Sadiq, MD, FAAN
Violaine K. Harris, PhD
Tamara Vyshkina, PhD
Gloria Joo, BA
Valentina Stefanova, MS